11/16
06:03 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/15
09:09 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $5.00.
High
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $5.00.
11/13
08:30 am
cmpx
Compass Therapeutics to Participate in Upcoming Investor Events
High
Report
Compass Therapeutics to Participate in Upcoming Investor Events
11/12
08:00 am
cmpx
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Medium
Report
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
11/11
08:09 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/8
10:10 am
cmpx
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Low
Report
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
11/8
10:05 am
cmpx
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/4
10:31 am
cmpx
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Low
Report
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
9/16
08:02 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.
9/3
08:00 am
cmpx
Compass Therapeutics to Participate in Upcoming Investor Events
Medium
Report
Compass Therapeutics to Participate in Upcoming Investor Events